TD 3504

Drug Profile

TD 3504

Alternative Names: TD-3504

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Theravance Biopharma
  • Class
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 14 Nov 2016 Theravance Biopharma plans a phase I trial for Ulcerative colitis
  • 08 Sep 2016 Phase-I clinical trials in Ulcerative colitis (In adults) in USA (NCT03103412)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top